Early Trial Offers New Hope for People With Hemophilia
Title: Early Trial Offers New Hope for People With HemophiliaCategory: Health NewsCreated: 9/9/2020 12:00:00 AMLast Editorial Review: 9/10/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - September 10, 2020 Category: Anesthesiology Source Type: news

Early Trial Offers New Hope for People With Hemophilia
WEDNESDAY, Sept. 9, 2020 -- Researchers may have found a way for people with severe hemophilia to take their standard treatment less often, if the results of an early trial pan out. In what experts called a feat of bioengineering, scientists were... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 9, 2020 Category: General Medicine Source Type: news

Are new treatments for haemophilia  A value for money?
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2020 Category: Drugs & Pharmacology Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

Paying for cell and gene therapy - Is the future already here?
The ascent of cell and gene therapies over the past few years has been astonishing. And their rise looks unstoppable: By 2025, the FDA expects it will be reviewing 10 to 20 of these transformative drugs per year.    But as we listen to affordability concerns from payers, providers and patients, we ’ve also had to ask, perhaps a bit provocatively, how we can afford to pay for this boom in future cures?  " Without solutions to help payers manage the cost, some of our members may make the choice to exclude coverage " , stated insurer CVS Health earlier in the year in its position paper on ...
Source: EyeForPharma - August 25, 2020 Category: Pharmaceuticals Authors: Ulrich Neumann Source Type: news

After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
A controversial drug to treat the most common form of dwarfism is heading for a federal regulator's decision. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) of San Rafael said Thursday that it submitted its new drug application for the Food and Drug Administration to approve its drug, called vosoritide, as a once-daily injection for children with achondroplasia. The bone-growth disorder prevents cartilage fr om changing into bone. The application comes a day after the FDA rejected BioMarin's request… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
A controversial drug to treat the most common form of dwarfism is heading for a federal regulator's decision. BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) of San Rafael said Thursday that it submitted its new drug application for the Food and Drug Administration to approve its drug, called vosoritide, as a once-daily injection for children with achondroplasia. The bone-growth disorder prevents cartilage fr om changing into bone. The application comes a day after the FDA rejected BioMarin's request… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 20, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

FDA blocks much-anticipated BioMarin hemophilia gene therapy
BioMarin Pharmaceutical shares plunged by a third after U.S. regulators rejected its potentially game-changing gene therapy for hemophilia A patients (Source: ABC News: Health)
Source: ABC News: Health - August 19, 2020 Category: Consumer Health News Tags: Health Source Type: news

Promising gene therapy against hemophilia rejected by FDA
BioMarin had gone so far as to give its hemophilia A gene therapy a name. Now it will have to deliver more data to the FDA. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 19, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Include Indigenous People in COVID-19 Response
Credit: Nidwan.By Pratima GurungKATHMANDU, Jul 28 2020 (IPS) In Nepal the COVID-19 crisis has been especially hard on indigenous peoples. We had to learn a new vocabulary and use words like quarantine, self-isolation, hand sanitizers and social distancing. We also had to respect rules that did not previously apply to our lives. Indigenous peoples are not used to washing their hands all the time because our culture is so much closer to Mother Earth and because much of the time we don’t have running water. The situation has been even more difficult for indigenous persons with a disability, like me. I cannot keep my so...
Source: IPS Inter Press Service - Health - July 28, 2020 Category: International Medicine & Public Health Authors: Pratima Gurung Tags: Asia-Pacific Headlines Health Human Rights Indigenous Rights Source Type: news

A new cell & gene therapy approach to treat common bleeding disorder
(Wake Forest Baptist Medical Center) WFIRM researchers have developed an optimized cellular platform for delivering Factor 8 to better treat patients with hemophilia A. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 28, 2020 Category: International Medicine & Public Health Source Type: news

Gene Therapy Shows Promise For Hemophilia, But Could Be Most Expensive U.S. Drug Ever
(Source: NPR Health and Science)
Source: NPR Health and Science - July 20, 2020 Category: Consumer Health News Authors: Rob Stein Source Type: news

Roche, Genentech ink real-world data deal with PicnicHealth
The original focus will be on multiple sclerosis but will  extend to include Huntington's disease and hemophilia.   (Source: mobihealthnews)
Source: mobihealthnews - July 16, 2020 Category: Information Technology Source Type: news

Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress
Dear Investor, Please find attached a press release by Spark Therapeutics:https://sparktx.com/press_releases/isth2020/ Do not hesitate to contact us for any further questions. With best regards, (Source: Roche Investor Update)
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

New data from phase IIIb study reinforces safety profile of Roche ’s Hemlibra in people with haemophilia A
Roche today announced results from the second interim analysis of the phase IIIb STASEY study, which reinforce the safety profile of Hemlibra ® (emicizumab) characterised in the phase III HAVEN clinical programme. (Source: Roche Media News)
Source: Roche Media News - July 13, 2020 Category: Pharmaceuticals Source Type: news

New data from phase IIIb study reinforces safety profile of Roche ’s Hemlibra in people with haemophilia A
Basel, 13 July 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from the second interim analysis of the phase IIIb STASEY study, which reinforce the safety profile of Hemlibra ® (emicizumab) characterised in the phase III HAVEN clinical programme.1,2,3 In the STASEY study, Hemlibra was effective with no new safety signals identified in adults and adolescents with haemophilia A with factor VIII inhibitors, which was consistent with previous safety observations.1 Further new interim data suggest that people on Hemlibra may be able to undergo certain minor surgeries without additional preventative (prophy...
Source: Roche Investor Update - July 13, 2020 Category: Pharmaceuticals Source Type: news

IDELVION(R) Becomes First and Only Factor IX Therapy with 21-Day Prophylactic Dosing
European Medicines Agency Approves 21-Day Dosing Intervals for Adult Haemophilia B Patients HATTERSHEIM, Germany, July 3, 2020 -- (Healthcare Sales & Marketing Network) -- Global biotherapeutics leader CSL Behring announced today that the European Medi... Biopharmaceuticals, Regulatory CSL Behring, IDELVION , albutrepenonacog alfa, Factor IX, haemophilia B (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 3, 2020 Category: Pharmaceuticals Source Type: news

Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene ther...
Source: Roche Media News - June 29, 2020 Category: Pharmaceuticals Source Type: news

Roche announces new data at the ISTH 2020 Congress, demonstrating ongoing commitment to advancing care for people with haemophilia A
Basel, 29 June 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its haemophilia A clinical programme will be presented at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress on 12-14 July 2020. Data will include updated safety results from the phase IIIb STASEY study of Hemlibra ® (emicizumab) and new results from the phase III HAVEN 5 study of Hemlibra. Data will also include insights into the impact of living with haemophilia A. Spark Therapeutics (a member of the Roche Group) will also present data from the initial dose cohorts of its phase I/II SPK-8011 gene ther...
Source: Roche Investor Update - June 29, 2020 Category: Pharmaceuticals Source Type: news

Why four years is important for BioMarin, hemophilia patients
An experimental gene therapy for hemophilia A from BioMarin Pharmaceutical Inc. — promising a one-shot fix for the genetic cause of the bleeding disorder — continues to hold patients' bleeds to less than one a year after four years. The results of the ongoing study are important as San Rafael-based BioMarin's (NASDAQ: BMRN) gene therapy, called Roctavian and known scienti fically as valoctogene roxaparvovec, nears an Aug. 21 decision date from the Food and Drug Administration. If approved, it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 1, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

2 Bay Area companies ramp up in quests for one-shot-and-done gene therapies
As BioMarin Pharmaceutical Inc. eyes a groundbreaking approval this summer of a one-shot-and-done treatment for hemophilia A patients, it and another Bay Area gene therapy company made big steps Monday. BioMarin (NASDAQ: BMRN) of San Rafael paired with one-year-old Swiss company DiNAQOR AG to develop gene therapies to treat rare genetic heart diseases and Adverum Biotechnologies Inc. (NASDAQ: ADVM) of Redwood City reported that the latest cohort in its early-stage clinical trial of patients with… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 4, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news

Sports participation and sports injuries in Dutch boys with haemophilia - Versloot O, Timmer M, de Kleijn P, Schuuring M, van Koppenhagen CF, van der Net J, Fischer K.
INTRODUCTION: Sports participation in children with haemophilia is generally considered to be associated with increased injury risk, which is generally considered highest in severe haemophilia. AIM: To assess sports participation according to age a... (Source: SafetyLit)
Source: SafetyLit - April 7, 2020 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

FDA Approves Sevenfact [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
LOUISVILLE, Ky., April 6, 2020 /PRNewswire/ -- HEMA Biologics, LLC, ( " HEMA Biologics " ) today announced that the U.S. Food and Drug Administration (FDA) approved Sevenfact® [coagulation factor VIIa (recombinant)-jncw] as the first new bypassing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 6, 2020 Category: Drugs & Pharmacology Source Type: news

HEMA Biologics(TM) Announces FDA Approval of SEVENFACT(R) [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
First new bypassing agent approved for the treatment and control of bleeding episodes in hemophilia A and B patients with inhibitors in over 2 decades Median number of infusions required to achieve bleeding control in the first 12 hours was 1 (225 mcg/k... Biopharmaceuticals, FDA HEMA Biologics, SEVENFACT, coagulation factor VIIa, hemophilia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 6, 2020 Category: Pharmaceuticals Source Type: news

FDA Approves Sevenfact (coagulation factor VIIa [recombinant]-jncw) for Adults and Adolescents with Hemophilia A or B and Inhibitors
April 01, 2020 -- The U.S. Food and Drug Administration today approved Sevenfact [coagulation factor VIIa (recombinant)-jncw] for the treatment and control of bleeding episodes occurring in adults and adolescents 12 years of age and older with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 1, 2020 Category: Drugs & Pharmacology Source Type: news

Health Tip: Coping With Winter Nosebleeds
-- Wintry climates and cold viruses can lead to frequent nosebleeds, says the National Hemophilia Foundation. To prevent nosebleeds during winter, the foundation suggests: Use a humidifier to moisturize the air. Use a nasal saline spray or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 10, 2020 Category: General Medicine Source Type: news

Gene therapy shown to offer long-term benefits for people with Haemophilia A
(Queen Mary University of London) A breakthrough gene therapy treatment for Haemophilia A has been shown to offer long-term benefits that have already transformed the lives of 13 men in the UK. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2020 Category: International Medicine & Public Health Source Type: news

Gene Therapy May Be Long-Term Cure for Type of Hemophilia
Title: Gene Therapy May Be Long-Term Cure for Type of HemophiliaCategory: Health NewsCreated: 1/2/2020 12:00:00 AMLast Editorial Review: 1/3/2020 12:00:00 AM (Source: MedicineNet Chronic Pain General)
Source: MedicineNet Chronic Pain General - January 3, 2020 Category: Anesthesiology Source Type: news

Gene Therapy May Be Long-Term Cure for Type of Hemophilia
THURSDAY, Jan. 2, 2020 -- A new gene therapy appears to serve as a functional cure for the most common type of hemophilia, early clinical trial results indicate. Patients who received the one-time intravenous therapy continue to have a more than... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 2, 2020 Category: General Medicine Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 23, 2019 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Hepatitis gene therapy leads Bay Area trio of year-end FDA approval requests
Approaching the end of long drug-development journeys, these three Bay Area companies formally asked the FDA to approve potential treatments for hemophilia A, anemia in chronic kidney disease patients and migraines. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - December 23, 2019 Category: Biotechnology Authors: Ron Leuty Source Type: news

European Medicines Agency Validates BioMarin's Marketing Authorization Application for Valoctocogene Roxaparvovec to Treat Severe Hemophilia A
Potential 1st Gene Therapy in Europe Directed at Any Type of Hemophilia Application to be Reviewed Under Accelerated Assessment SAN RAFAEL, Calif., Dec. 23, 2019 -- (Healthcare Sales & Marketing Network) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN... Biopharmaceuticals, Regulatory BioMarin Pharmaceutical, valoctocogene roxaparvovec, hemophilia A, gene therapy (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2019 Category: Pharmaceuticals Source Type: news

BioMarin Submits Biologics License Application to U.S. Food and Drug Administration for Valoctocogene Roxaparvovec to Treat Hemophilia A
SAN RAFAEL, Calif., Dec. 23, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today that the company submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 23, 2019 Category: Drugs & Pharmacology Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche concludes acquisition of Spark Therapeutics, Inc. to strengthen presence in gene therapy
Spark will continue its operations in Philadelphia as an independent company within the Roche Group             Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced the completion of the acquisition following the receipt of regulatory approval from all government authorities required by the merger agreement. Commenting on this important step forward, Severin Schwan, CEO of Roche, said, “We are excited about this important milestone because we believe that together...
Source: Roche Investor Update - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche purchases shares in tender offer for Spark Therapeutics, Inc.
Basel, 17 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that Roche’s wholly owned subsidiary 022019 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Spark, at a price of USD 114.50 per share in ca sh.  The tender offer expired at 5:00 p.m., New York City time, on 16 December 2019 and was not extended. Roche has been advised by Citibank, N.A., the depositary for the tender offer, that a total of appr...
Source: Roche Media News - December 17, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in the Offer to Purchas...
Source: Roche Media News - December 16, 2019 Category: Pharmaceuticals Source Type: news

Roche and Spark Therapeutics, Inc. announce unconditional clearance by UK Competition and Markets Authority
             Basel, 16 December 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ( “Spark”) today announced that the UK Competition and Markets Authority has unconditionally cleared Roche’s pending acquisition of Spark pursuant to its previously announced tender offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Sha re, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subjec...
Source: Roche Investor Update - December 16, 2019 Category: Pharmaceuticals Source Type: news

Highmark Establishes High-Performance Hemophilia Partnership
Highmark announced a new partnership focused on the treatment and management of hemophilia, which aims to ensure that members receive hemophilia drugs from organizations that meet rigorous performance...(PRWeb November 19, 2019)Read the full story at https://www.prweb.com/releases/highmark_establishes_high_performance_hemophilia_partnership/prweb16725465.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 19, 2019 Category: Pharmaceuticals Source Type: news

Putting a Price on Life: Is the Answer Outside Pharma?
 To cure the previously incurable we must take two giant steps: the first towards better understanding the science behind a cure, and the second towards ensuring accessibility for those people in need of the treatment.   Although there is still much to discover, we got the science right some time ago. The first gene replacement therapy – Gendicine (Shenzhen SiBiono GeneTech) – was approved in China in 2003 and has been successfully administered to more than 30,000 patients with head and neck squamous cell carcinoma. A single dose of this medication costs $400.  Another example of early ...
Source: EyeForPharma - November 4, 2019 Category: Pharmaceuticals Authors: Nicola Davies Source Type: news

1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
Prevalence of all severities of hemophilia A and hemophilia B estimated at 17.1 and 3.8 cases per 100,000 (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 10, 2019 Category: Cancer & Oncology Tags: Family Medicine, Internal Medicine, Oncology, Pediatrics, Journal, Source Type: news

1,125,000 Men/Boys Expected to Have Hemophilia Worldwide
TUESDAY, Sept. 10, 2019 -- The expected number of patients with hemophilia worldwide is 1,125,000 male patients, with 418,000 severe cases, according to research published online Sept. 10 in the Annals of Internal Medicine. Alfonso Iorio, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 10, 2019 Category: Pharmaceuticals Source Type: news

Hemophilia disease 3 times more prevalent than previously thought, study finds
In a new study published Monday, researchers at Hamilton's McMaster University say more than 1,125,000 men around the world have hemophilia, and 418,000 of those have a severe version of the mostly undiagnosed disease. (Source: CBC | Health)
Source: CBC | Health - September 9, 2019 Category: Consumer Health News Tags: News/Canada/Hamilton Source Type: news

NHS to fund 'life changing' haemophilia drug
Emicizumab mimics the action of factor VIII to stem uncontrolled bleeds Related items fromOnMedica Child health should be election priority say experts and public Government launches its Child Health Strategy Cash-injection for sick children UK lagging behind other comparable countries on young people ’s health England falling behind on child health (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 22, 2019 Category: UK Health Source Type: news

'Trailblazing' treatment that prevents bleeds in haemophiliacs will be available on NHS England
Emicizumab, which mimics the missing protein, can be injected under the skin as little as every two weeks. It is now available after NHS England agreed to fund the drug, sold under the brand name Hemlibra. (Source: the Mail online | Health)
Source: the Mail online | Health - August 21, 2019 Category: Consumer Health News Source Type: news

New drug for people who can bleed uncontrollably
NHS England is funding a new treatment for patients with severe haemophilia A. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - August 21, 2019 Category: Consumer Health News Source Type: news

Life-changing drug to stop deadly bleeding available on the NHS
NHS England is to fund a life-changing treatment for thousands of people with severe haemophilia, which will dramatically cut their risk of life-threatening bleeds and reduce treatment time. (Source: NHS Networks)
Source: NHS Networks - August 21, 2019 Category: UK Health Source Type: news

Bayer recalls two lots of mislabeled hemophilia A med
The drugmaker is voluntarily recalling two lots that were filled with factor VIII hemophilia A treatment Jivi but were labeled as containing hemophilia treatment Kogenate FS (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - July 23, 2019 Category: Pharmaceuticals Source Type: news

Boy with bruises whose parents were 'accused of abusing him' diagnosed with a rare blood condition
Jack Fearns, of Cheshire, was six months old when his parents, Tom and Darryl-Anne Ferns, felt interrogated by doctors. Jack was diagnosed with haemophilia. (Source: the Mail online | Health)
Source: the Mail online | Health - July 19, 2019 Category: Consumer Health News Source Type: news

Dosing Differences Opined for Costly Hemophilia Option Dosing Differences Opined for Costly Hemophilia Option
Achieving the goal of zero bleeds as patients pursue active lives will require divergent dosing, according to PROPEL trial investigators who evaluated whether more exposure to FVIII improves outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 12, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news